Biography
Nicolas Lee is an associate in Weil’s Private Equity practice and is based in Dallas. Nicolas participates in the representation of private equity sponsors and their portfolio companies with respect to mergers, acquisitions and divestitures.
Nicolas has been part of the teams advising:
- Graycliff Partners in its acquisition of a majority stake in Landmark Structures I, LP
- Kainos Capital in its acquisition of Microbe Formulas LLC
- PSG in its sale of Sovereign Sportsman Holdings, LLC to PayIt, LLC; Netsurion LLC in sale of its Secure Edge Networking business segment to Acumera, Inc. and in sale of substantially all of the remaining assets to Lumifi Cyber, Inc.; Shieldco Holdings LP in its acquisition of Threatswitch, Inc.; and in a Series C funding round for, and in a separate, secondary purchase of common shares of, Code Climate Inc.
- Vehlo Holdings LP (a portfolio company of Greater Sum Ventures) in its acquisition of Rapid Recon, Inc.
Prior to joining Weil, Nicolas was a Corporate associate at another international law firm.
Nicolas received his J.D., magna cum laude, from Southern Methodist University School of Law, where he served as an Articles Editor of the SMU International Law Review. He received his M.S. from Southern Methodist University, where he was a recipient of the Kitt Fellowship, and his B.A., cum laude, from the University of Dallas.
Awards and Recognition, Speaking Engagements, Guides and Resources, Latest Thinking, Firm News & Announcements
Latest Thinking
- Weil Private Equity Sponsor Sync - Spring Issue Publication — By Christopher R. Machera, Andrew J. Colao, Jacqueline Oveissi, Arnie Fridhandler, Brittany Butwin, David Griffiths, Alex Paul Cohen, David E. Wohl, Carson Parks, Nicolas Lee, Trey Muldrow, Langdon Neal, Timothy F. Burns, David B. Gail, John P. Barry, Robert Rizzo, Larissa Lucas, Yehudah L. Buchweitz and Zoe Buzinkai — PDF — Spring 2024
Firm News & Announcements
- Weil Secures Major Victory for Religious Freedom in New York Litigation Win — May 24, 2024
- Weil Guides Ad Hoc Group of Lenders in Covis Pharma's Cross Border Restructuring Deal Brief — June 01, 2023